Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers

International Journal of Clinical Oncology

Volumn 19, Issue 3, 2014, Pages 467-472

  Yanai, Ayako ^a   Miyagawa, Yoshimasa ^a   Murase, Keiko ^a   Imamura, Michiko ^a   Yagi, Tomoko ^a   Ichii, Shigetoshi ^a   Takatsuka, Yuichi ^a   Ito, Takashi ^a   Hirota, Seiichi ^a   Sasa, Mitsunori ^b   Katagiri, Toyomasa ^c   Miyoshi, Yasuo ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Tokushima Breast Care Clinic   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Body mass index; Breast cancer; Estrogen receptor; Ki67

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; ERBB2 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; JAPANESE (PEOPLE); LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OBESITY; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; BREAST TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; POSTMENOPAUSE;

ADULT; BODY MASS INDEX; BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 84903315982     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0585-y     Document Type: Article

References (16)

1. Renehan AG, Tyson M, Egger M et al (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569-578 (Pubitemid 351232031)
2. Harvie M, Hooper L, Howell AH (2003) Central obesity and breast cancer risk: a systematic review. Obes Rev 4(3):157-173 (Pubitemid 36950578)
3. McTiernan A, Rajan KB, Tworoger SS et al (2003) Adiposity and sex hormones in postmenopausal breast cancer survivors. J Clin Oncol 21(10):1961-1966 (Pubitemid 46606384)
4. Phipps AI, Malone KE, Porter PL et al (2008) Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 17(8):2078-2086
5. Berclaz G, Li S, Price KN et al (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 15(6):875-884 (Pubitemid 39004342)
6. Kawai M, Minami Y, Nishino Y et al (2012) Body mass index and survival after breast cancer diagnosis in Japanese women. BMC Cancer 12:149
7. Sparano JA, Wang M, Zhao F et al (2012) Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer (Phila) 118(23):5937-5946
8. Dawood S, Lei X, Litton JK et al (2012) Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer. Clin Breast Cancer 12(5):364-372
9. Sestak I, Distler W, Forbes JF et al (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28(21):3411-3415
10. Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736-750
11. Biglia N, Peano E, Sgandurra P et al. (2013) Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women. Gynecol Endocrinol 29(3):263-267
12. Daling JR, Malone KE, Doody DR et al (2001) Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer (Phila) 92(4): 720-729 (Pubitemid 32783055)
13. Goodwin PJ, Ennis M, Pritchard KI et al (2002) Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 20(1):42-51 (Pubitemid 34032594)
14. Goodwin PJ, Ennis M, Bahl M et al (2009) High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat 114(3):517-525
15. IrwinML, Duggan C, WangCY et al (2011) Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol 29(1):47-53
16. Viale G, Regan MM, Maiorano E et al (2008) Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors. International Breast Cancer Study Group. J Clin Oncol 26(9):1404-1410